Literature DB >> 16848050

Lyme borreliosis and Borrelia spielmanii.

Vera Maraspin, Eva Ruzic-Sabljic, Franc Strle.   

Abstract

Entities:  

Mesh:

Year:  2006        PMID: 16848050      PMCID: PMC3291061          DOI: 10.3201/eid1207.060077

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: A report on erythema migrans (EM) caused by Borrelia spielmanii in a recent issue of Emerging Infectious Diseases () was a stimulus for a review of data on this Borrelia species in patients with early Lyme borreliosis (LB). We report a patient with EM, examined at our LB outpatient clinic, from whom B. spielmanii was isolated from the skin lesion. The presence of this species was ascertained by using a 5S–23S spacer amplicon after digestion with MseI and demonstration of fragments having sizes typical for B. spielmanii (106, 68, and 51 bp) (). A 69-year-old woman was examined on October 30, 1996, for a skin lesion on her left thigh. Her medical history indicated arterial hypertension, intermittent pain in the cervical and lumbar region due to spondylosis, frequent headaches and myalgias, and treatment of typical EM skin lesions at our LB outpatient clinic in 1992 and 1994; the latter lesions were culture positive for Borrelia. Fourteen days before examination, she noticed a small area of redness, accompanied by mild local itching, burning, and pain on her left knee. On examination, a 24 × 20–cm ringlike lesion was found on her left thigh. Basic blood tests did not show abnormal results, and a serum sample was negative for borrelial antibodies (immunofluorescence test using a B. afzelii skin isolate as antigen) (). However, B. spielmanii was isolated from an EM skin biopsy specimen. The patient was treated with amoxicillin, 500 mg 3 times a day for 15 days. The skin lesion disappeared within 3 weeks, and a culture of a repeat skin biopsy specimen was negative for Borrelia 2 months after the first biopsy. Her clinical course during a 1-year follow-up was uneventful. B. spielmanii was detected in the patient by a general approach we have used for several years. In all consenting patients, a skin specimen from an EM lesion is cultured for borreliae in modified Kelly medium before and, in case of a positive result, ≈2 months after antimicrobial drug treatment is started. Isolated strains are typed by using the 5S–23S spacer amplicon. The findings in this report are generally consistent with those in other reports of adult patients with EM (–). One difference was that the patient did not report a tick bite at the site of the EM. Approximately two thirds of our patients with EM recalled a tick bite and ≈10% of patients treated for early LB had previously had EM (–). Previous reports indicate several differences in patients with EM caused by B. burgdorferi and B. afzelii () and patients with EM caused by B. afzelii and B. garinii (,). Some of the findings in our patient are unusual and rarely found in those with early LB. However, the small number of patients infected with B. spielmanii (1 reported herein and 4 previously reported) does not allow any reliable conclusion to be made on differences in clinical manifestations of LB caused by B. spielmanii compared with those of other species. Our results corroborate previous findings that B. spielmanii is a cause of LB in Europe. Thus, in addition to the Netherlands (), Germany (), and Hungary (), LB caused by B. spielmanii is also present in Slovenia.
  9 in total

1.  Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia.

Authors:  F Strle; R B Nadelman; J Cimperman; J Nowakowski; R N Picken; I Schwartz; V Maraspin; M E Aguero-Rosenfeld; S Varde; S Lotric-Furlan; G P Wormser
Journal:  Ann Intern Med       Date:  1999-01-05       Impact factor: 25.391

2.  Characteristics of erythema migrans in Borrelia afzelii and Borrelia garinii infections.

Authors:  Sten-Anders Carlsson; Hans Granlund; Christian Jansson; Dag Nyman; Peter Wahlberg
Journal:  Scand J Infect Dis       Date:  2003

3.  Phenotypic and genetic characterization of a novel Borrelia burgdorferi sensu lato isolate from a patient with lyme borreliosis.

Authors:  G Wang; A P van Dam; J Dankert
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

4.  Clinical and epidemiological findings for patients with erythema migrans. Comparison of cohorts from the years 1993 and 2000.

Authors:  Franc Strle; Jerneja Videcnik; Peter Zorman; Joze Cimperman; Stanka Lotric-Furlan; Vera Maraspin
Journal:  Wien Klin Wochenschr       Date:  2002-07-31       Impact factor: 1.704

5.  Evaluation of immunofluorescence test (IFT) and immuno (western) blot (WB) test in patients with erythema migrans.

Authors:  Eva Ruzić-Sabljić; Vera Maraspin; Joze Cimperman; Stanka Lotric-Furlan; Franc Strle
Journal:  Wien Klin Wochenschr       Date:  2002-07-31       Impact factor: 1.704

6.  Has the presence or absence of Borrelia burgdorferi sensu lato as detected by skin culture any influence on the course of erythema migrans?

Authors:  M Logar; S Lotric-Furlan; V Maraspin; J Cimperman; T Jurca; E Ruzić-Sabljić; F Strle
Journal:  Wien Klin Wochenschr       Date:  1999-12-10       Impact factor: 1.704

7.  European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans.

Authors:  F Strle; J A Nelson; E Ruzic-Sabljic; J Cimperman; V Maraspin; S Lotric-Furlan; Y Cheng; M M Picken; G M Trenholme; R N Picken
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

8.  Comparison of erythema migrans caused by Borrelia afzelii and Borrelia garinii.

Authors:  M Logar; E Ruzić-Sabljić; V Maraspin; S Lotric-Furlan; J Cimperman; T Jurca; F Strle
Journal:  Infection       Date:  2004-02       Impact factor: 3.553

9.  Borrelia spielmanii erythema migrans, Hungary.

Authors:  Gábor Földvári; Róbert Farkas; András Lakos
Journal:  Emerg Infect Dis       Date:  2005-11       Impact factor: 6.883

  9 in total
  15 in total

1.  Reservoir competence of various rodents for the lyme disease Spirochete Borrelia spielmanii.

Authors:  Dania Richter; Daniela B Schlee; Franz-Rainer Matuschka
Journal:  Appl Environ Microbiol       Date:  2011-04-01       Impact factor: 4.792

Review 2.  Updates on Borrelia burgdorferi sensu lato complex with respect to public health.

Authors:  Nataliia Rudenko; Maryna Golovchenko; Libor Grubhoffer; James H Oliver
Journal:  Ticks Tick Borne Dis       Date:  2011-05-27       Impact factor: 3.744

3.  Red Foxes (Vulpes vulpes) Are Exposed to High Diversity of Borrelia burgdorferi Sensu Lato Species Infecting Fox-Derived Ixodes Ticks in West-Central Poland.

Authors:  Beata Wodecka; Jerzy Michalik; Renata Grochowalska
Journal:  Pathogens       Date:  2022-06-16

4.  In vitro susceptibility of Borrelia spielmanii to antimicrobial agents commonly used for treatment of Lyme disease.

Authors:  Kristina Morgenstern; Georg Baljer; Douglas E Norris; Peter Kraiczy; Christa Hanssen-Hübner; Klaus-Peter Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  Versatile roles of CspA orthologs in complement inactivation of serum-resistant Lyme disease spirochetes.

Authors:  Claudia Hammerschmidt; Arno Koenigs; Corinna Siegel; Teresia Hallström; Christine Skerka; Reinhard Wallich; Peter F Zipfel; Peter Kraiczy
Journal:  Infect Immun       Date:  2013-11-04       Impact factor: 3.441

6.  Human pathogenic Borrelia spielmanii sp. nov. resists complement-mediated killing by direct binding of immune regulators factor H and factor H-like protein 1.

Authors:  Pia Herzberger; Corinna Siegel; Christine Skerka; Volker Fingerle; Ulrike Schulte-Spechtel; Alje van Dam; Bettina Wilske; Volker Brade; Peter F Zipfel; Reinhard Wallich; Peter Kraiczy
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

7.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

8.  Nucleic Acid Amplification Based Diagnostic of Lyme (Neuro-)borreliosis - Lost in the Jungle of Methods, Targets, and Assays?

Authors:  Oliver Nolte
Journal:  Open Neurol J       Date:  2012-11-16

9.  Design and development of a novel vaccine for protection against Lyme borreliosis.

Authors:  Pär Comstedt; Markus Hanner; Wolfgang Schüler; Andreas Meinke; Urban Lundberg
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

Review 10.  Treatment of Lyme borreliosis.

Authors:  Hermann J Girschick; Henner Morbach; Dennis Tappe
Journal:  Arthritis Res Ther       Date:  2009-12-17       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.